These YGP-activated monocytes exert direct cytotoxicity against tumor cells in vitro, and systemic YGP treatment increases the levels of inflammatory mediators such as TNF-α, M-CSF, and CCL2 in the lungs. Here, CSF1 is linked to neoplasm.